Myeloid Malignancies
Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are central areas of interest, with studies extending to related relapsed or refractory disease settings and combinations used in hematologic oncology.
- Acute myeloid leukemia (AML)
- Myelodysplastic syndromes (MDS)
- Chronic myelomonocytic leukemia (CMML)
- Relapsed/refractory hematologic disease
Research activity in this area includes oral decitabine/cedazuridine programs and other regimens directed at bone marrow disorders.
Lung Cancer and EGFR-Driven Disease
Non-small cell lung cancer is a major focus, particularly tumors with EGFR exon 20 insertion, uncommon EGFR mutations, and acquired resistance alterations.
- Locally advanced or metastatic non-small cell lung cancer
- EGFR exon 20 insertion mutations
- Uncommon and compound EGFR mutations
- Post-surgical lung cancer settings
Investigational work also includes targeted approaches for EGFR-mutant solid tumors and treatment-resistant disease.
Other Solid Tumors
The sponsor supports research across a broad range of advanced solid tumors, including urothelial carcinoma, cholangiocarcinoma, cervical carcinoma, and head and neck squamous cell carcinoma.
- Urothelial carcinoma
- Cholangiocarcinoma
- Cervical carcinoma
- Head and neck squamous cell carcinoma
Additional studies include metastatic solid tumors and tumors with HER2 aberrations, reflecting interest in molecularly defined oncology populations.
Lymphomas and T-Cell Malignancies
Clinical research also covers peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and diffuse large B-cell lymphoma, along with other aggressive or relapsed lymphoma subtypes.
- Peripheral T-cell lymphoma
- Cutaneous T-cell lymphoma
- Diffuse large B-cell lymphoma
- Relapsed or refractory lymphoma
These studies include therapies aimed at advanced lymphoid malignancies and difficult-to-treat recurrent disease.
Healthy Volunteer and Pharmacokinetic Research
Some trials focus on healthy volunteers and patients with cancer to characterize pharmacokinetics, metabolism, drug-drug interactions, and organ impairment considerations for oncology agents.
- Pharmacokinetic profiling
- Metabolism and mass balance
- Drug interaction assessment
- Renal and hepatic impairment
This area includes support for oral targeted therapies and combination oncology treatments in both cancer and non-cancer populations.
